ST2 Biomarker Risk Tier Calculator

Clinical calculation support · Verify results before clinical use

Enter biomarker result

Enter the measured soluble ST2 concentration in ng/mL to view its category and clinical context.

Use the units reported by the laboratory and confirm the assay-specific reference information.

About soluble ST2

Soluble ST2 (sST2) is a member of the interleukin-1 receptor family and is studied as a biomarker associated with myocardial stress, remodeling, and prognosis in heart failure. It may add prognostic information alongside clinical assessment and natriuretic peptides.

The original calculator used three bands: below 35, 35–70, and above 70 ng/mL. These bands are retained for continuity, but they should be treated as a simplified categorization rather than a universally validated risk score.

Thresholds used in this calculator

sST2 concentrationCategory shownImportant limitation
<35 ng/mLLowerDoes not exclude heart failure or adverse outcomes.
35–70 ng/mLIntermediateInterpretation depends on clinical setting and assay.
>70 ng/mLHigherProposed in selected acute-HF approaches; not a universal treatment threshold.

Clinical use

  • Interpret alongside symptoms, examination, imaging, natriuretic peptides, and other relevant data.
  • Thresholds may perform differently in acute versus chronic heart failure.
  • Do not use this simplified category alone to diagnose heart failure, determine disposition, or change treatment.

References

Januzzi JL Jr, et al. Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea: Results From the PRIDE Study.

Journal of the American College of Cardiology. 2007.

doi:10.1016/j.jacc.2007.05.014
Rehman SU, et al. Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure.

Journal of the American College of Cardiology. 2008;52:1458–1465.

doi:10.1016/j.jacc.2008.07.042
Aimo A, Maisel AS, Castiglione V, Emdin M. sST2 for Outcome Prediction in Acute Heart Failure: Which Is the Best Cutoff?

JACC. 2019. Discusses the limitations of applying a single sST2 cutoff across acute and chronic HF settings.

JACC article
Bayés-Genís A, Núñez J, Lupón J. Soluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard?

Journal of the American College of Cardiology. 2017;70:2389–2392.

doi:10.1016/j.jacc.2017.09.031
Clinical disclaimer: This calculator displays a simplified sST2 concentration category and is not a validated standalone risk score. Prognostic thresholds vary by population, clinical setting, assay, and outcome. Results must be interpreted by a qualified clinician within the full clinical context.